MedTrace Logo

Docosahexenoic Acid (DHA) Supplementation and Cardiovascular Disease in Men With High Triglycerides

NCT00728338 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 40

Last updated 2008-08-08

No results posted yet for this study

Summary

The purpose of this study is to determine the effects of supplementing diets of hyperlipidemic men with DHA (docosahexenoic acid) on risk factors for cardiovascular disease. We hypothesize that supplementing diets of hyperlipidemic men with DHA will decrease the plasma concentrations of CRP (C-reactive protein), inflammatory cytokines, and soluble adhesion molecules. We further hypothesize that DHA supplementation will decrease serum triglyceride concentrations and increase HDL concentration.

Conditions

  • Hypertriglyceridemia

Interventions

DIETARY_SUPPLEMENT

Docosahexenoic acid (DHA)

The DHA group received 7.5 g/d DHA oil (DHA 3.0 g/d) which is produced in the microalga Crypthecodinium cohinii.

DIETARY_SUPPLEMENT

Olive oil

7.5 g olive oil/day

Sponsors & Collaborators

  • VA Northern California Health Care System

    collaborator FED

  • DSM Nutritional Products, Inc.

    collaborator INDUSTRY

  • USDA, Western Human Nutrition Research Center

    lead FED

Principal Investigators

  • Darshan S Kelley, PhD · USDA, ARS, WHNRC

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
39 Years
Max Age
66 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2003-06-30
Primary Completion
2005-11-30
Completion
2005-11-30

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00728338 on ClinicalTrials.gov